Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) Stock Holdings Boosted by Fifth Third Bancorp

Fifth Third Bancorp grew its stake in Jazz Pharmaceuticals PLC (NASDAQ:JAZZ - Free Report) by 769.5% in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 3,617 shares of the specialty pharmaceutical company's stock after buying an additional 3,201 shares during the period. Fifth Third Bancorp's holdings in Jazz Pharmaceuticals were worth $449,000 at the end of the most recent reporting period.

Other large investors have also modified their holdings of the company. IFP Advisors Inc acquired a new stake in shares of Jazz Pharmaceuticals in the 4th quarter worth $25,000. Quadrant Capital Group LLC increased its holdings in Jazz Pharmaceuticals by 97.1% during the 4th quarter. Quadrant Capital Group LLC now owns 205 shares of the specialty pharmaceutical company's stock valued at $25,000 after acquiring an additional 101 shares in the last quarter. Elequin Capital LP grew its holdings in shares of Jazz Pharmaceuticals by 677.8% during the fourth quarter. Elequin Capital LP now owns 210 shares of the specialty pharmaceutical company's stock worth $26,000 after buying an additional 183 shares in the last quarter. CoreFirst Bank & Trust purchased a new stake in shares of Jazz Pharmaceuticals during the fourth quarter worth about $28,000. Finally, Allianz SE purchased a new stake in shares of Jazz Pharmaceuticals during the fourth quarter worth about $29,000. Institutional investors and hedge funds own 89.14% of the company's stock.

Analysts Set New Price Targets

Several equities research analysts recently issued reports on JAZZ shares. JPMorgan Chase & Co. raised their target price on shares of Jazz Pharmaceuticals from $200.00 to $209.00 and gave the stock an "overweight" rating in a research report on Wednesday, February 26th. Cantor Fitzgerald cut shares of Jazz Pharmaceuticals from an "overweight" rating to a "neutral" rating and raised their target price for the stock from $140.00 to $150.00 in a research report on Wednesday, February 26th. Truist Financial lifted their price target on shares of Jazz Pharmaceuticals from $220.00 to $230.00 and gave the company a "buy" rating in a research report on Thursday, March 6th. Wall Street Zen cut shares of Jazz Pharmaceuticals from a "buy" rating to a "hold" rating in a research report on Thursday, May 15th. Finally, Morgan Stanley reduced their price target on shares of Jazz Pharmaceuticals from $183.00 to $166.00 and set an "overweight" rating on the stock in a research report on Wednesday, May 7th. Two research analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company's stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $184.00.

Jazz Pharmaceuticals Stock Up 1.1%

Shares of NASDAQ JAZZ traded up $1.19 during trading on Thursday, reaching $108.24. 601,574 shares of the stock were exchanged, compared to its average volume of 832,582. The business's 50-day moving average price is $108.00 and its 200 day moving average price is $120.18. Jazz Pharmaceuticals PLC has a twelve month low of $95.49 and a twelve month high of $148.06. The company has a quick ratio of 2.97, a current ratio of 3.38 and a debt-to-equity ratio of 1.28. The company has a market capitalization of $6.55 billion, a price-to-earnings ratio of 14.43, a price-to-earnings-growth ratio of 4.67 and a beta of 0.33.

Jazz Pharmaceuticals (NASDAQ:JAZZ - Get Free Report) last posted its quarterly earnings results on Tuesday, May 6th. The specialty pharmaceutical company reported $1.68 earnings per share (EPS) for the quarter, missing the consensus estimate of $4.65 by ($2.97). The company had revenue of $897.84 million during the quarter, compared to analyst estimates of $984.16 million. Jazz Pharmaceuticals had a net margin of 11.86% and a return on equity of 26.62%. The company's revenue was down .5% on a year-over-year basis. During the same period in the prior year, the company earned $2.68 earnings per share. As a group, equities analysts forecast that Jazz Pharmaceuticals PLC will post 16.96 EPS for the current fiscal year.

Insider Activity at Jazz Pharmaceuticals

In related news, Director Seamus Mulligan purchased 100,000 shares of the business's stock in a transaction that occurred on Friday, May 9th. The shares were purchased at an average cost of $98.26 per share, with a total value of $9,826,000.00. Following the completion of the acquisition, the director now directly owns 100,000 shares of the company's stock, valued at approximately $9,826,000. The trade was a ∞ increase in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Bruce C. Cozadd sold 1,500 shares of the business's stock in a transaction on Tuesday, April 1st. The shares were sold at an average price of $123.75, for a total transaction of $185,625.00. Following the sale, the chief executive officer now owns 440,307 shares of the company's stock, valued at approximately $54,487,991.25. The trade was a 0.34% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 3,000 shares of company stock valued at $355,925 over the last ninety days. Corporate insiders own 4.30% of the company's stock.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.